found no significant increase in thyroid cancer risk (HR = 0.95; 95% CI: 0.79–1.14) when comparing DPP‐4 inhibitors, such as linagliptin, to SGLT2 inhibitors [40]. The gene discussed is DPP4; the disease is thyroid gland carcinoma.